A board structured for early-stage R&D, sized to expand with the company.

SnowLabs Limited operates with a small board today, with reserved seats for an independent non-executive director, a scientific advisory chair, and a financial-oversight director. Each reserved seat carries a defined appointment trigger — usually a capital event, a multi-resort commercial deployment, or a regulatory milestone.

Current composition

Seat	Holder	Role
Founder & Chief Executive Director	Mitchell McLennan	Strategic direction, capital, commercial relationships, group-wide product strategy. Chairs the board.
Independent Non-Executive Director	Reserved — to be appointed at first qualifying capital event.	Independent challenge on strategy, capital allocation, and executive performance. Chair of the Audit Committee once appointed.
Scientific Advisory Chair	Reserved — to be appointed during 2026.	Polymer chemistry, ice physics, or cold-chain biology expertise. Reviews scientific roadmap and signs off on regulatory dossiers prior to filing.
Financial Oversight Director	Reserved — to be appointed alongside first statutory audit.	Liaison with audit firm; chair of the Audit Committee in the interim until an independent NED is appointed.

Appointment principles

Board appointments are made by the existing directors against three criteria: relevant domain expertise (polymer chemistry, EU industrial chemistry regulation, cold-chain commercial scale-up, or licensing-business operations); demonstrated independence from the founder’s personal network; and willingness to attend a minimum of six scheduled board meetings per year plus ad-hoc convenings around financing or material commercial events. Directors are appointed for a renewable two-year term and are subject to annual self-assessment.